← Return to Clinical Trials: they are not designed only to be a “last resort”

Discussion
Comment receiving replies
@stageivsurvivor

Your situation may even be simpler. Physicians can prescribe a medication approved for another use as “Off-label drug” use mwaninf that a drug that’s been approved by the FDA for one purpose is used for a different purpose that has not been approved. The provision in FDA regulations allows a doctor to prescribe the FDA approved drug for another purpose. The FDA regulates the testing and approval of drugs, but not how doctors use drugs to treat their patients.

The difference in my situation is PARPi’s we’re just being tested for the first time with pancreatic cancer and the trials were accepting both PDAC and PACC forms and somatic and germline BRCA mutations. Now there is history of it working in PDAC and limited data with PDAC because it is such a rare form. I was likely the first PACC patient it was tested on and was successful.

Jump to this post


Replies to "Your situation may even be simpler. Physicians can prescribe a medication approved for another use as..."

You're a weath of information, sir. I'm feeling more assured that if I'm still here in June of '26, the end of my NIH trial, I'll be able to continue using the Olaparib. And if anyone reading this forum has pancreatic acinar cell cancer, and also has the BRCA2 mutation, the clinical trial I'm in is still looking for participants. They are looking for 20 patients but so far I'm the only one in the trial. The NIH protocol title for the trial is "000596-C: Phase II study of Olaparib in subjects with advanced Pancreatic Acinar Cell Carcinoma". The contact doctor is Christine Alewine. I don't have her ph. no. handy. I was concerned that, since this study is government funded, they might pull the plug on it due to lack of participants. Dr. Alewine said, "That's not going to happen." I'm hoping some others come forward.